We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Metabolic Study of Highly Active Antiretroviral Therapy (HAART) in Malnourished Children With HIV (ARMAM)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01529125
First Posted: February 8, 2012
Last Update Posted: January 23, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Washington University School of Medicine
February 3, 2012
February 8, 2012
January 23, 2014
July 2011
September 2012   (Final data collection date for primary outcome measure)
Pharmacokinetics [ Time Frame: 6 weeks ]
PK of ART in malnourished children
Not Provided
Complete list of historical versions of study NCT01529125 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Safety and Metabolic Study of Highly Active Antiretroviral Therapy (HAART) in Malnourished Children With HIV
ART Pharmacokinetics, Mitochondrial Integrity, and Antioxidant Capacity in Severely Malnourished HIV-infected Malawian Children
It is unclear whether children with HIV and severe acute malnutrition can be started on highly active antiretroviral therapy (HAART) safely while they are still malnourished and the manner in which this therapy should start. This study will examine the safety, efficacy, and metabolism of children started on HAART while still severely malnourished.
Not Provided
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Children aged 6-59 months with HIV and kwashiorkor and marasmus who are not currently on HAART will be recruited from the Nutritional Rehabilitation Unit at Queen Elizabeth Central Hospital in Blantyre, Malawi. Controls will be recruited from the outpatient cotrimoxazole clinic who are about to start on HAART for a non-nutritional reason.
  • Kwashiorkor
  • Marasmus
  • Severe Acute Malnutrition
  • HIV
Drug: zidovudine, lamivudine, nevirapine
  • Kwashiorkor
    HIV-positive children aged 6-59 months with kwashiorkor receiving nutritional rehabilitation and who are started on HAART.
    Intervention: Drug: zidovudine, lamivudine, nevirapine
  • Marasmus
    HIV-positive children aged 6-59 months with marasmus receiving nutritional rehabilitation and who are started on HAART.
    Intervention: Drug: zidovudine, lamivudine, nevirapine
  • Control
    HIV-positive children aged 6-59 months who are not severely malnourished and who are started on HAART for a non-nutritional reason.
    Intervention: Drug: zidovudine, lamivudine, nevirapine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
42
September 2012
September 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • HIV-infected about to start on HAART for the first time
  • 6-59 months old

Exclusion Criteria:

  • also being treated for TB
  • other chronic illness (e.g., congenital heart disease, cerebral palsy)
Sexes Eligible for Study: All
6 Months to 59 Months   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Malawi
 
 
NCT01529125
ARTMAM
No
Not Provided
Not Provided
Washington University School of Medicine
Washington University School of Medicine
Not Provided
Principal Investigator: Mark J Manary, MD Washington University School of Medicine
Washington University School of Medicine
January 2014